Biodesix Inc (BDSX) ニュース

Is selling $250 million in stock fro time to time on the downside.. Separately, Biodesix filed a registration statement to sell up to $250 million in securities from time to time.

Lung diagnostics cancer revenues improving still has $33m cash $1.49 +'14%

$BDSX - Up 12%/ Current Price $1.34.
Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

WOOOOOOW 130K SHARES BUY NOW 2.6 MIL SHARE BUY $

3 MILLION $ BUY $$$$$$$$$$$$$$$$$$$$$$

Lots if potential but will public offering dilute price?

Lots if potential but will public offering dilute price?

Earnings look good.

Earnings look good.

BDSX Has news this morning!

The contract covers the company’s entire lung diagnostic portfolio: Nodify XL2®, Nodify CDT®, VeriStrat®, GeneStrat® ddPCR, and GeneStrat NGS™ testing.

https://investors.biodesix.com/news-releases/news-release-details/biodesix-awarded-us-federal-supply-schedule-contract-its

https://stockcharts.com/h-sc/ui?s=BDSX

Not so much...

LET'S GO BDSX !!!!!

Biodesix to Participate in Two Upcoming Investor Conferences in September
6:00 am ET September 6, 2022 (BusinessWire) Print
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at www.biodesix.com.

H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 Format: 1x1 meetings Location: Lotte New York Palace Hotel, New York, NY

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

US based company is quietly trending up. IMHO.
GLTA